Resmed cites momentum, continued progress in Q3 

SAN DIEGO – Resmed reported revenue increased by 11% to $1.4 billion for the third quarter fiscal year 2026. 

Other financial results: 

• GAAP gross margin up 290 bps to 62.2%; non-GAAP gross margin up 290 bps to 62.8% 
• GAAP income from operations increased 17%; non-GAAP income from operations up 18% 
• GAAP diluted earnings per share of $2.74; non-GAAP diluted earnings per share of $2.86 
• Operating cash flow of $554 million; $262 million returned to shareholders through share repurchases and dividends 

“Our third quarter results reflect the continued strength of our global business, driven by ongoing demand for our market-leading products and disciplined execution of our strategy,” said Chairman and CEO Mick Farrell. "Year-over-year, we delivered 11% reported revenue growth, 290 basis points of non-GAAP gross margin expansion, and 21% increase in earnings per share. These results highlight the momentum behind our strategy, and the continued progress we are making in shaping the future of sleep health, breathing health, and healthcare in the home.” 

Revenue in the U.S., Canada and Latin America, excluding Residential Care Software, grew by 9%. Revenue for Residential Care Software grew 4%. 

Among the highlights for the quarter: 

• Unveiled findings from sixth annual Global Sleep Survey, drawing insights from 30,000 people across 13 countries; as sleep awareness grows, so does the opportunity to turn intent into action. 
• Announced expansion of U.S. operations with new distribution center in Greenwood, Indiana, scheduled to begin operations in 2027 and expand Resmed’s U.S. presence while strengthening the company's distribution capacity to better serve patients and providers across North America. 
• Launched the AirTouch F30i Comfort full face mask in the U.S. following its introduction in Australia and Canada, and building on the launch of the AirTouch F30i Clear in the U.S. 

Resmed also announced that CFO Brett Sandercock plans to retire May 4. He will be replaced by Aaron Bloomer, who joins the company from Exact Sciences, a cancer diagnostics company recently acquired by Abbott.